Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2024-09-09
Target enrollment:
Participant gender:
Summary
HER2-targeted therapy after the failure of trastuzumab treatment has become a new difficulty
and challenge. Inetetamab, a new antibody to optimize the ADCC effect, has become one of the
second-line treatment options after trastuzumab fails, showing good survival benefits.
Pyrotinib, another second-line HER2 targeted drug, is a typical representative of TKI drugs,
which not only has a strong HER2 antagonistic effect but also can synergize with monoclonal
antibodies to amplify the ADCC effect. Pyrotinib and Inetetamab showed excellent anti-tumor
efficacy and good safety in TKI and optimized ADCC respectively. we plan to carry out a phase
II single-arm clinical study to evaluate the efficacy and safety of "Inetetamab combined with
Pyrotinib and chemotherapy" in the treatment of her positive metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University